A phase 1 dose-escalation study of protein arginine methyltransferase 5 (PRMT5) inhibitor PRT543 in patients with advanced solid tumors and lymphoma

Meredith McKean, Manish R Patel, Robert Wesolowski, Renata Ferrarotto, Eytan M. Stein, Alexander N Shoushtari, David Mauro, John Viscusi, Peggy Scherle, Neha Bhagwat, William Sun, Rachel Chiaverelli, Eric Mintah, Shekeab Jauhari, Laura Finn, Neil D. Palmisiano, Robert A Baiocchi. AACR-NCI-EORTC Annual Meeting 2021; October 7-10, 2021.